These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486 [TBL] [Abstract][Full Text] [Related]
48. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer. Dalal AA; Guerin A; Mutebi A; Culver KW J Med Econ; 2018 Jul; 21(7):649-655. PubMed ID: 29516752 [TBL] [Abstract][Full Text] [Related]
49. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas. Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436 [TBL] [Abstract][Full Text] [Related]
50. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761 [TBL] [Abstract][Full Text] [Related]
51. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study. Paz-Ares L; Gondos A; Saldana D; Thomas M; Mascaux C; Bubendorf L; Barlesi F Lung Cancer; 2022 May; 167():41-48. PubMed ID: 35397297 [TBL] [Abstract][Full Text] [Related]
52. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns. Clavé S; Rodon N; Pijuan L; Díaz O; Lorenzo M; Rocha P; Taus Á; Blanco R; Bosch-Barrera J; Reguart N; de la Torre N; Oliveras G; Espinet B; Bellosillo B; Puig X; Arriola E; Salido M Clin Lung Cancer; 2019 Jul; 20(4):e421-e429. PubMed ID: 30898567 [TBL] [Abstract][Full Text] [Related]
53. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1. Liu J; Liu Y Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773 [TBL] [Abstract][Full Text] [Related]
54. Resistance Mechanisms to Targeted Therapies in McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358 [No Abstract] [Full Text] [Related]
55. Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L. Sakata S; Otsubo K; Yoshida H; Ito K; Nakamura A; Teraoka S; Matsumoto N; Shiraishi Y; Haratani K; Tamiya M; Ikeda S; Miura S; Tanizaki J; Omori S; Yoshioka H; Hata A; Yamamoto N; Nakagawa K Cancer Sci; 2022 Jan; 113(1):221-228. PubMed ID: 34704312 [TBL] [Abstract][Full Text] [Related]
56. Somatic mutations and immune checkpoint biomarkers. Parris BA; Shaw E; Pang B; Soong R; Fong K; Soo RA Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374 [TBL] [Abstract][Full Text] [Related]
57. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532 [TBL] [Abstract][Full Text] [Related]
58. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update. Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519 [TBL] [Abstract][Full Text] [Related]
59. Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer. Kuang S; Fung AS; Perdrizet KA; Chen K; Li JJN; Le LW; Cabanero M; Karsaneh OAA; Tsao MS; Morganstein J; Ranich L; Smith AC; Wei C; Cheung C; Shepherd FA; Liu G; Bradbury P; Pal P; Schwock J; Sacher AG; Law JH; Stockley TL; Leighl NB Curr Oncol; 2022 Jun; 29(7):4428-4437. PubMed ID: 35877212 [TBL] [Abstract][Full Text] [Related]
60. Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung Adenocarcinoma. Oezkan F; Herold T; Darwiche K; Eberhardt WEE; Worm K; Christoph DC; Wiesweg M; Freitag L; Schmid KW; Theegarten D; Hager T; Koenig MJ; He K; Taube C; Schuler M; Breitenbuecher F Clin Lung Cancer; 2018 Nov; 19(6):e879-e884. PubMed ID: 30206042 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]